Table 1.
Baseline characteristics of all patients.
| Characteristic | Right-sided cancer (N = 385) | Left-sided cancer (N = 632) | P value |
|---|---|---|---|
| Age (years) | 67(59–77) | 65.3 (57–75) | < 0.01 |
| Sex, Male, N (%) | 182 (47.3%) | 357 (56.5%) | < 0.01 |
| Body mass index | 23.7 ± 4.4 | 24.5 ± 4.1 | < 0.01 |
| Patient origin, N (%) | 0.12 | ||
| Elective operation | 301 (78.2%) | 519 (82.1%) | |
| Emergency operation | 84 (21.8%) | 113 (17.9%) | |
| Operation method, N (%) | < 0.01 | ||
| Open surgery | 202 (52.5%) | 238 (37.7%) | |
| Minimal invasive surgery | 183 (47.5%) | 394 (62.3%) | |
| CEA | 3.3 (1.7–9.4) | 3.6 (1.9–8.7) | 0.39 |
| Tumor size (cm) | 4.5 (3.2–6.4) | 4.0 (3.0–5.5) | < 0.01 |
| Lymphovascular invasion, N (%) | 185 (48.1%) | 304 (48.1%) | 0.99 |
| Perineural invasion, N (%) | 148 (38.4%) | 230 (36.4%) | 0.51 |
| Tumor grade, N (%) | 0.03 | ||
| Grade 1–2 | 355 (92.2%) | 604 (95.6%) | |
| Grade 3–4 | 30 (7.8%) | 28 (4.4%) | |
| Location | |||
| Cecum, N (%) | 70 | ||
| Ascending colon, N (%) | 166 | ||
| Hepatic flexure, N (%) | 50 | ||
| Transverse colon, N (%) | 99 | ||
| Splenic flexure, N (%) | 35 | ||
| Descending colon, N (%) | 38 | ||
| Descending-sigmoid junction, N (%) | 46 | ||
| Sigmoid colon, N (%) | 513 | ||
| T stage, N (%) | |||
| T1 | 41 (10.6%) | 86 (13.6%) | 0.05 |
| T2 | 39 (10.1%) | 83 (13.1%) | |
| T3 | 214 (55.6%) | 351 (55.5%) | |
| T4 | 91 (23.6%) | 112 (17.7%) | |
| N stage, N (%) | |||
| N0 | 217 (56.4%) | 293 (46.4%) | 0.01 |
| N1 | 106 (27.5%) | 221 (35.0%) | |
| N2 | 62 (16.1%) | 118 (18.7%) | |
| AJCC stage, N (%) | |||
| I | 66 (17.1%) | 122 (19.3%) | < 0.01 |
| II | 151 (39.2%) | 171 (27.1%) | |
| III | 168 (43.6%) | 339 (53.6%) | |
| No. of lymph node harvested | 26 (19–35.5) | 21 (16–28) | < 0.01 |
| Adjuvant chemotherapy, N (%) | 197 (51.2%) | 323 (51.1%) | 0.99 |
| K-ras mutation, No. of positive/No. of test (%) | 94/194 (48.5%) | 93/294 (31.6%) | < 0.01 |
| dMMR, No. of positive/No. of test (%) | 25/55 (45.5%) | 10/55 (18.2%) | < 0.01 |
| MSI-H, No. of positive/No. of test (%) | 5/20 (25%) | 1/13 (7.7%) | 0.21 |
| R1 resection, N (%) | 17 (4.4%) | 19 (3.0%) | 0.24 |
| Follow time (month) | 37.8 (23.5–63.5) | 43.0 (25.3–67.5) | 0.12 |
Significant values are in bold.
CEA carcinoembryonic antigen, dMMR Deficient mismatch repair, MSI-H microsatellite instability-high.